arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Processa Pharmaceuticals, Inc.

PCSA
$1.89 ▼ -0.01 (-0.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Processa Pharmaceuticals, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -198.1% ↗
FCF / Share $-8.70 ↘
Trailing P/E —
Price / Book 19.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-13.56M
↓ -14.5% —
FCF / Share Free cash flow per share
$-8.70
↓ -136.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Financial Health ↓
2
Cash Quality ↑
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 15 years · 57 quarters